[Acute non ST-elevation coronary syndrome in real practice of hospitals in Russia. Comparative data from RECORD 2 and RECORD registries].
Kardiologiia · 2012-01-01 · Registry study
Abstract
AIM: to compare data on pre- and in hospital treatment of non ST-elevation (NSTE) acute coronary syndromes (ACS) in Russian ACS registers RECORD (recruitment from 11.2007 to 02.2008) and RECORD-2 (from 04/2009 to 04.2011). MATERIAL: Four of 7 hospitals participating in RECORD-2 were invasive (57.1% vs. 55.6% in RECORD). In RECORD-2 10-30 consecutive patients with NSTEACS were included monthly in each center; recruitment in RECORD was described elsewhere. RESULTS: Mean age of patients was similar in two registries. Portion of women was significantly higher in RECORD-2 (42.9% vs. 26.0% in RECORD; <0.0001). Although markers of necrosis were measured in higher proportion of patients in RECORD-2, frequency of troponin determination was not significantly different (47.0 vs. 43.5% in RECORD; =0.64). Patients in RECORD-2 more frequently received prehospital aspirin (51.6 vs 33.5%; <0.0001), aspirin in recommended initial dose 160-325 mg (64.3 vs. 47.1%; =0.03), and clopidogrel during hospitalization (47.0 vs. 27.6%; <0.0001). Rates of in hospital use of parenteral anticoagulants in both registries were similar, but among anticoagulants in RECORD 2 proportion of fondaparinucs became noticeable (9.5%) and that of low molecular weight heparin (LMWH) became significantly higher (21.2 vs. 11.6% in RECORD). Almost one third of patients in RECORD-2 who were treated with unfractionated heparin (UFH) received it subcutaneously. About half of patients treated with intravenous infusion of UFH received it for less than 48 hours. Although higher proportion of patients hospitalized in invasive hospitals were subjected to diagnostic coronary angiography in RECORD-2 (80.8 vs. 54.3% in RECORD; <0.0001) differences between registries in rates of percutaneous coronary interventions (PCI) (all - 37.3 vs. 29.9%; =0.051; first 72 hours - 22.7 vs. 24.8%; =0.55), and coronary artery bypass graftings (5.6 vs. 5.8%; =0.12) were not significant. There were no significant differences in rates of any in hospital unfavorable events. Analysis of treatment and outcomes in groups of high risk patients (GRACE score >140) gave results close to those in all patients except mortality which was statistically similar but numerically higher in RECORD-2 (9.3 vs. 7.9% in RECORD; p=0.68). CONCLUSION: Comparison of data of 2 limited NSTEACS registers conducted with interval of about 2 years showed only modest shift towards fulfillment of contemporary recommendations which was not associated with increase in rates of PCI and improvement of outcomes especially in high risk patients.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Antithrombotics & thrombolytics · Acetylsalicylic acid · Heparin · Mortality & survival · P2Y12 inhibitors
Related articles
- Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies. (Eur J Emerg Med, 2009)
- Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. (J Am Coll Cardiol, 2010)
- Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: correlates of reperfusion before primary PCI. (J Electrocardiol, 2011)
- Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. (J Am Coll Cardiol, 2007)
- Risk of bleeding after prehospital administration of high dose tirofiban for ST elevation myocardial infarction. (Int J Cardiol, 2012)
- Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. (Am Heart J, 2007)